Next-generation bioinks for high-fidelity 3D bioprinting.

Modern drug development still relies on flat 2D cell cultures that fail to represent human tissue, and on animal models that poorly predict human response. This results in development timelines that stretch into decades and approval costs that reach into the billions. The same bottleneck also keeps artificial organs further out of reach. We believe 3D bioprinting can break this deadlock — by enabling spatially controlled disease models that mimic human environments, and by laying the groundwork for full-scale printed tissues and organ structures.

Elva Bio is a spin-out from the University of Helsinki, founded by four scientists with deep roots in polymer chemistry, cell biology, and materials science. Born from years of academic research, we are now translating scientific breakthroughs into practical tools for drug developers, tissue engineers, and researchers worldwide.

The key to bioprinting lies in the material itself — the bioink. Today, researchers are forced to choose between cytocompatibility and high-resolution printing. Our materials eliminate this trade-off, enabling precise, high-resolution printing without compromising cell viability. They can function either as standalone bioinks or as additives that enhance existing formulations, allowing seamless integration into all current bioprinting workflows.